1.
Rev Esp Enferm Dig
; 113(12): 858-859, 2021 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34696593
RESUMO
Secukinumab is a monoclonal antibody that inhibits interleukin-17A. It is currently prescribed for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis, which are immune-mediated diseases that show significant co-heritability with inflammatory bowel disease (IBD). Although this treatment appears to be well tolerated by patients, several cases of new-onset IBD after secukinumab have been reported during the last years.